Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q2 FY26 Earnings Presentation
34 slides from Poly Medicure's earnings presentation, Nov 8, 2025
Slide 1: Submission of Investor's Presentation cover letter
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110 020 {INDIA) ·,, IPOLYMED T+91-ll - 33550700, 47317000 E: info@polymedicure.com W: polymedicure.com GIN: L 40300DL 1995PLC066923 Date: 08th November, 2025 Scrip Code: - 531768 Scrip Code:- POLYME
Slide 2: Investor Presentation Q2 FY26 Results
Investor Presentation Poly Medicure Ltd. Q2 FY26 Results 08th Nov 2025
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as
Slide 4: Consolidated Performance Summary Q2 FY26 & H1 FY26
Consolidated Performance Summary Q2 FY 26 & H1 FY26 Figs in Rs. Crs unless specified Margin,% Revenue Operating EBITDA1 PAT 26.5% 26.8% 27.6% 26.7% 27.4% 20.9% 19.2% 19.6% 20.0% 19.0% 443.9 93.1 847.1 118.8 225.9 184.9 91.8 115.9 420.0 220.2 804.8 107.0 87.5 161.5 403.2 Q1 FY26 Q2 FY26 Q2 FY25 H1 FY
Slide 5: Agenda: Key Updates
Agenda Key Updates
Slide 6: Key Updates
Key Updates • Completed acquisitions of PendraCare Group – Netherlands (Cardiology) and Citieffe Group – Italy (Orthopaedics) • YTD ~4,300 stents implanted with positive feedback received from patients and clinicians • Clinical study on RisoR stent initiated in India and Europe Key Business • YTD Oc
Slide 7: Citieffe – fully integrated Trauma and Extremity supplier with global sales footprint
Citieffe – fully integrated Trauma and Extremity supplier with global sales footprint Vertically integrated developer, manufacturer and distributor of Trauma and Extremity fixation systems … Citieffe With diversified revenue base Key Products Core Business Split, CY24 Founded in 1962, Located in Bol
Slide 8: PendraCare – A Unique Interventional Cardiology consumable business in Europe
PendraCare – A Unique Interventional Cardiology consumable business in Europe PendraCare – One-of-a-kind opportunity With diversified revenue base Key Products Core Business Split, CY24 EXISTING UNDER Located in Leek Netherlands DEBVELOPMENT Guiding OEM catheter Product registration in more than 60
Slide 9: Launched PACE- Polymed Academy of Clinical Excellence
Launched PACE- Polymed Academy of Clinical Excellence ▪ A Center of Excellence dedicated to scientific learning, customer engagement, innovation, and professional knowledge-sharing ▪ Aims to establish Polymed as a preferred partner for scientific training, learning & development 8
Slide 10: Enhanced Usage of AI to optimize learning
Enhanced Usage of AI to optimize learning SARATHII -Strategic AI Resource for Advanced Training & Holistic In-clinic Interactions Inspired from the Hindi word used for Mentor / Coach Revolutionizing Medical Sales Training: Introducing AI-Powered Role-Plays AI-powered Initiative providing immersive t
Slide 11: IV talks - Monthly affair to engage with nursing fraternity
IV talks - Monthly affair to engage with nursing fraternity on national level A Joint Program with INS Key Highlights ▪ CNE : 518 Nursing engagements conducted Pan-India in Q2 ▪ RTMs : 11 round table meets with Doctors/ Senior nursing leaders Pan- India in Q2 FY26 ▪ ASCENT+ : 14 cities in 12 states,
Slide 12: Participation in International Exhibitions
Participation in International Exhibitions Thailand Malaysia Indonesia Vietnam 11
Slide 13: Participation in Domestic Events and KOL Engagement
Participation in Domestic Events and KOL Engagement (Hony) Brig. Dr Arvind Lal’s visit at our plant (Hony) Brig. Dr Arvind Lal Participation at India Bold Voices Podcast Medtech Expo Mr. Gautam Khanna Dr Harsh Mahajan Dr Sanjeev Singh 12
Slide 14: Agenda: Consolidated Financial Performance Summary
Agenda Consolidated Financial Performance Summary
Slide 15: Consolidated Financial Performance Summary
Consolidated Financial Performance Summary Figs in Rs. Cr. unless specified YoY Growth QoQ Growth YoY Growth Particulars Q2 FY 26 Q2 FY 25 Q1 FY 26 H1 FY 26 H1 FY 25 % % % Revenue from Operations 443.9 420.0 5.7% 403.2 10.1% 847.1 804.8 5.3% Cost of Good Sold 135.7 132.5 2.4% 127.2 6.6% 262.9 260.8
Slide 16: Consolidated Sales Performance Analysis
Consolidated Sales Performance Analysis Figs in Rs. Crs unless specified YoY QoQ YoY Particulars Q2 FY 26 Q2 FY 25 Q1 FY 26 H1 FY 26 H1 FY 25 Growth % Growth % Growth % Domestic 140.9 120.5 16.9% 125.7 12.1% 266.5 225.2 18.3% International 300.3 296.2 1.4% 275.2 9.1% 575.4 573.9 0.3% Other Operating
Slide 17: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified YoY YoY QoQ Particulars Q2 FY26 Q2 FY25 Q1 FY 26 H1 FY 26 H1 FY 25 Growth Growth % Growth % % Infusion Therapy 273.5 280.3 (2.4%) 251.8 8.6% 525.3 536.5 (2.1%) Renal 44.2 37.5 18.1% 43.5 1.7% 87.7 67.3 30.3% Others 125.9 102.3
Slide 18: Balance Sheet
Balance Sheet Figs in Rs. Crs unless specified Consolidated Particulars As at Sep 30, 2025 As at March 31, 2025 Total Shareholders Funds 2,932.5 2,765.7 Equity Share Capital 50.7 50.7 Other Equity 2,867.7 2,715.0 Non Controlling Interest 14.1 Total Debt 236.2 177.6 Short Term Borrowings 236.2 177.6
Slide 19: Cash Flow Summary
Cash Flow Summary Figs in Rs. Crs unless specified Particulars H1 FY 26 EBITDA 225.9 Other operating income and non cash expense 17.4 Tax Paid (43.8) Operating Cash Flow before WC Changes 199.4 Investment in Working Capital Changes in Inventory (39.1) Changes in Debtors (50.0) Changes in Payables 19
Slide 20: Return Ratios
Return Ratios ROCE ROE * 23% 23%* 19% 18%* 19% 20%** 15% 15%** FY 23 FY 24 FY 25 Sep'25 FY 23 FY 24 FY 25 Sep'25 * Excludes the amount raised through QIP in August 2024, EBIT has been computed after excluding the treasury income generated from the QIP Funds ** Calculated based on trailing 12 months
Slide 21: Shareholding Pattern as on September 30th 2025
Shareholding Pattern as on September 30th 2025 Others 14.3% Foreign Portfolio Investors 9.8% Insurance Companies 2.8% 2.7% Alternate Investment Funds 62.4% Promoters & Promoter Group 8.0% Mutual Funds 20
Slide 22: Agenda: Polymed Overview and Way Forward
Agenda Polymed Overview and Way Forward
Slide 23: Polymed at a Glance
Polymed at a Glance 13 14 Manufacturing Plants Specialities Across 5 countries 125+ Countries 200+ Medical Devices 3500+ Employee Base 540+ Sales Associates 375+ Patents Granted 900+ 1.8 Billion+ Devices Manufacturing Capacity Distributors across India & Globally Per year 22
Slide 24: Navigating Our Journey
Navigating Our Journey Polymed’s Path of Milestones and Triumphs QIP 2 INR 1,000Cr raised QIP 1 INR 400Cr raised Cardiology & 2024 Critical Care PolyHealth Medical 2021 (US subsidiary of Poly Medicure ) 2019 2016 2011 2003 2007 2025 Acquired Company New R&D Plan1 Health, Joint Venture in Haridwar li
Slide 25: Awards & Accolades
Awards & Accolades Mr Himanshu Baid, MD, Poly Medicure Himanshu Baid, MD, Poly Medicure Himanshu Baid, MD, Poly Medicure Innovative Health Technology EY Entrepreneur of the Year Award 2024 - Healthcare Icon/Leader of the Year Healthcare Entrepreneur of the Year 2025 Provider of the Year by ET Rajast
Slide 26: Navigating the Path & beyond
Navigating the Path Building Tomorrow’s Healthcare Solutions Started In 2028 1997 2002-09 2011-19 2020-24 2025 - 27 & beyond Commencement Product and facility New R&D Center, of Manufacturing expansion Acq of Plan 1 Health, Operation New Manufacturing › Launched › Prioritize the › Through a Plants d
Slide 27: Polymed's Ecosystem (Manufacturing Process)
Polymed’s Ecosystem (Manufacturing Process) Clinical Support Distribution Network Sales & Marketing Product Concept Product Product Design Manufacturing Rapid Prototyping Product Packaging Regulatory Sterilization Compliance Tool Design Tool Manufacturing 26
Slide 28: Our Innovations Deliver Care to Key Clinical Specialties
Our Innovations Deliver Care to Key Clinical Specialties Cardiology Anaesthesia & Respiratory Care Transfusion System Oncology Vascular Access Infusion Therapy Gastroenterology Diagnostics Urology Dialysis & Renal Care Orthopedics Surgery & Wound Drainage Critical Care New Segment through Citieffe A
Slide 29: Diving into our Product Portfolio
Diving into our Product Portfolio Vascular Pre-filled Access Disinfecting Saline Syringe Central Venous Safety Introducer Safety Winged IV Cannula Cap IV Sets Three Way Stop Cock Catheters Needle Infusion Set Infusion Therapy Extension Lines with Infusion Set with Three Way Stop Cock Arterial Blood
Slide 30: Cardiology, Surgery and Wound Drainage product portfolio
Cardiology Diagnostic Catheter PTCA Balloon PTCA Balloon DES Hydrophilic Guidewire PTFE Coated Guidewire Dilation Catheter SC Dilation Catheter NC Guiding Catheter Closed Wound Surgery and Suction Unit Wound Drainage Closed Wound Centesis Catheter High Pressure Redon Under Water Thoracic Yankauer Ya
Slide 31: Polymed's Manufacturing Footprint
Polymed's Manufacturing Footprint 14 Facilities across 5 countries India Manufacturing Facilities International Manufacturing Facilities 117,Faridabad, India IMT 1,Faridabad, India SEZ 2, Jaipur, India Assuit, Egypt Amaro, Italy 104-105,Faridabad R&D Haridwar Plant, Laiyang- Plant, India Centre Indi
Slide 32: Way Forward
Way Forward Research & Development ▪ Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations Emphasizing Inorganic Growth ▪ Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expanding market reac
Slide 33: Towards our Commitment to a Sustainable World
Towards our Commitment to a Sustainable World Approx. 70% facilities are certified under Achieved ~1% reduction in Scope 2 ISO 14001:2015 during Q2 compared to the same period in ENVIRONMENTAL FY 24-25 MANAGEMENT SYSTEM SCOPE 2 EMISSION ▪ Annual Health check-up of 183 employees Q2-597 MW ▪ One on on
Slide 34: Thank You
Thank You For any investor related queries reach us at: aayur.verma@polymedicure.com 33